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Clinically localized prostate cancer is typically managed by well established therapies like
radical prostatectomy, brachytherapy, and external beam radiation therapy. While many
patients can be cured with deﬁnitive local therapy, some will have biochemical recurrence
(BCR) of disease detected by a rising serum prostate-speciﬁc antigen (PSA). Management
of these patients is nuanced and controversial.The natural history indicates that a majority
of patients with BCR will not die from prostate cancer but from other causes. Despite
this, a vast majority of patients with BCR are empirically treated with non-curable systemic
androgen deprivation therapy (ADT), with its myriad of real and potential side effects. In
this review article, we examined the very deﬁnition of BCR after deﬁnitive local therapy,
the current status of imaging studies in its evaluation, the need for additional therapies,
and the factors involved in the decision making in the choice of additional therapies. This
review aims to help clinicians with the management of patients with BCR. The assess-
ment of prognostic factors including absolute PSA level, time to recurrence, PSA kinetics,
multivariable nomograms, imaging, and biopsy of the prostatic bed may help stratify the
patients into localized or systemic recurrence. Patients with low-risk of systemic disease
may be cured by a salvage local therapy, while those with higher risk of systemic disease
may be offered the option of ADT or a clinical trial. An algorithm incorporating these factors
is presented.
Keywords: prostate cancer, radical prostatectomy, radiation therapy, biochemical recurrence, PSA recurrence,
salvage
INTRODUCTION
The most common primary local therapies used for clinically
localized prostate cancer are radical prostatectomy (RP) and radi-
ation therapy (RT), including external beam radiation therapy
(EBRT). While these primary therapies are associated with a
high cancer control rates for localized disease, up to a third of
patients undergoing these therapies will have a biochemical recur-
rence (BCR) after local therapy (Djavan et al., 2003; Khan et al.,
2003).
Biochemical recurrence is a clinical state characterized by a
rising serum prostate-speciﬁc antigen (PSA),with or without clin-
ical or radiographic metastasis. Patients with BCR have a variable
clinical course: some will have indolent course with no adverse
long-term effect on their survival; others may have a rapid clin-
ical progression, with metastasis to bone and increased risk of
Prostate Cancer Speciﬁc Mortality (PCSM). Comparison of out-
comes reveal that patients with BCR have a 88% 10-year overall
survival rate in contrast to the 93% 10-year overall survival rate in
men without BCR (Jhaveri et al., 1999). In a landmark paper eval-
uating BCR following RP, the median time from BCR to clinical
progression was noted to be 8 years and from metastasis to PCSM
was 5 years (Pound et al., 1999) indicating that median survival
from BCR was 13 years. While recent studies have demonstrated
even longer median survival after BCR (up to 16 years), a subset
of men with aggressive prostate cancer die much sooner after PSA
recurrence (Freedland et al., 2005).
This review will discuss the natural history of BCR, review
current management options for patients with BCR, and evalu-
ate management options after primary deﬁnitive treatment for
localized prostate cancer.
BCR DEFINITION
Prostate-speciﬁc antigens are typically evaluated every 3months
after surgery. Serum PSA should reach undetectable levels in
4weeks in amajority of cases of patients undergoingRP,as thehalf-
life of PSA is 2.5–3 days (Partin and Oesterling, 1994). A detectable
PSA may reﬂect presence of benign prostatic tissue left after RP
which may still produce PSA (Djavan et al., 2005). Often, serial
evaluation of PSAs can help evaluate the clinical signiﬁcance of
a detectable PSA. For example, a man with a detectable and low
PSA level of 0.05 ng/ml after RP may have a persistently detectable
PSA without signiﬁcant change for a long time. Such a patient
is unlikely to progress and suffer PCSM. Thus, a detectable PSA
after RP alone may not mandate salvage intervention. In contrast,
a patient with a detectable and serially rising PSA of 0.5 ng/ml after
RP is more indicative of residual prostate cancer and may beneﬁt
from salvage intervention.
Since a detectable PSA after RP alone does not indicate BCR,
several studies have evaluated if speciﬁc PSA cutoffs could deﬁne
BCR (Amling et al., 2001; Stephenson et al., 2006). EAU guidelines
deﬁne BCR with both a post-RP PSA cutoff of 0.2 ng/ml, and two
sequential PSA values ≥0.2 ng/ml (Aus et al., 2005). Indeed, only
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half of men with a detectable PSA in the 0.2–0.29 ng/ml range
had a subsequent PSA progression and could be deﬁned as hav-
ing BCR (Amling et al., 2001). A PSA level ≥0.4 ng/ml correlated
with a 79% risk of PSA progression (Amling et al., 2001). The
PSA Working Group deﬁned BCR with a PSA cutoff ≥0.4 ng/ml
with a subsequent elevated level (Scher et al., 2004). A retrospec-
tive evaluation of BCR criteria showed that PSA cutoff ≥0.4 ng/ml
had the highest correlation with the risk of clinical progression
(Stephenson et al., 2006).
Deﬁnition of BCR following RT is also controversial. Follow-
ing RT, PSA levels may not decrease to undetectable levels and
may settle at a stable detectable level., Further, PSA ﬂuctuations
(the so called “PSA bounce”) are common in the ﬁrst 2 years
after RT (Hanlon et al., 2001; Rosser et al., 2002; Sengoz et al.,
2003). Indeed, the median time to PSA nadir is 18months (Zagars,
1992). Finally, concomitant use of androgen deprivation therapy
(ADT) either prior to or along with RT complicates the inter-
pretation of BCR. Thus, unlike after RP, a single PSA cutoff for
BCR post-RT cannot be deﬁned. To address this issue, in 1997,
the American Society for Therapeutic Radiology and Oncology
(ASTRO) deﬁned BCR criteria as three consecutive rises in the
PSA level above nadir (American Society for Therapeutic Radi-
ology and Oncology Consensus Panel, 1997). Since the ASTRO
criteria didnot specify aPSAcutoff, amanwhose post-RTPSA rose
from a nadir of 0.05 ng/ml to 0.06, 0.07, and 0.08 ng/ml on sub-
sequent evaluations could be classiﬁed as having BCR. To address
this issue, in 2005, the Phoenix criteria for post-RT BCR were
deﬁned as PSA increase ≥2 ng/ml above nadir (Roach et al., 2006).
Currently, ASTRO criteria are typically used in RT-only treated
patients andPhoenix criteria in bothRT-only orRT+ADT treated
patients.
NATURAL HISTORY OF BCR
Up to a third of the 90,000 patients treated annually for clini-
cally localized prostate cancer will experience BCR. Among these
patients with BCR, one-third will eventually have clinical progres-
sion to metastases (Pound et al., 1999; Ward et al., 2003). A vast
majority of patients with BCR will die of other causes (DOC);
only those who progress to metastasis may suffer PCSM. Figure 1
illustrates the disease states of prostate cancer patients and their
likelihood of mortality from either PCSM or DOC.
EVALUATION OF PATIENTS WITH BCR
Biochemical recurrence may signify local or metastatic recur-
rence. Patients with localized recurrence may be managed with
localized salvage therapies. In contrast, patients with metastatic
recurrence require systemic salvage therapies. Thus, the evalua-
tion of patients with BCR is primarily to attempt stratiﬁcation into
local or metastatic recurrence, using strategies described below.
ABSOLUTE PSA LEVEL
The absolute serum PSA level after initial local therapy is an indi-
cator of the disease volume. Higher the PSA level, greater the
burden of recurrence, and higher the risk of metastatic disease.
A serum PSA level greater than 40 ng/ml is strongly associated
with metastatic recurrence (Zagars, 1992). Further, a serum PSA
level above 1 ng/ml indicates a higher risk of failure of localized
salvage therapy (Stephenson et al., 2004a).
FIGURE 1 | Disease states of localized prostate cancer patients and
their likelihood of mortality from either other causes (DOC, death of
other causes) or prostate cancer (PCSM, prostate cancer specific
mortality).The bold lines indicate a higher risk of mortality, while the
dotted lines indicate a lower risk of mortality. BCR, biochemical recurrence;
PCSM, prostate cancer speciﬁc mortality; DOC, death of other causes.
TIME TO RECURRENCE
The time period from initial local therapy to BCR has been shown
to correlate with the site of recurrence. A shorter time to BCR after
initial local therapy is associated with a higher risk of metastatic
recurrence. In contrast, a longer time toBCR after initial local ther-
apy is associated with a higher risk of localized recurrence (Pound
et al., 1999; Freedland et al., 2005). While a true cutoff of the time
to BCR has not been established, a time to BCR ≤2 years after RP
strongly implicates a distant or metastatic recurrence while a time
period of>2 years suggests a local recurrence (Pound et al., 1999).
PSA KINETICS
Generally, a shorter PSA doubling time (PSA-DT) indicates a
rapidly growing tumor, a higher risk of clinical progression to
metastatic disease and a higher risk of PCSM (Trapasso et al.,
1994; D’Amico et al., 2005). In one study, patients post-RP with
a longer PSA-DT (mean 11.7months) had a higher risk of local-
ized prostate cancer and a lower risk of clinical progression than
patients with a shorter PSA-DT (4.3months; Trapasso et al., 1994).
Patients with PSA-DT of <3months represented a minority (10–
15%) of men with BCR but had the highest risk of systemic recur-
rence (D’Amico et al., 2005). Similarly in men post-RT, systemic
recurrences were associated with higher PSA nadir and shorter
PSA-DT (Crook et al., 1998). Patients with a PSA-DT <3months
had the greatest risk of PCSM, with a median survival of 6 years
(D’Amico et al., 2003).
MULTIVARIABLE PREDICTION TOOLS
Multivariable prediction tools such as nomogramswere developed
using clinico-pathologic and biochemical risk factors such as PSA-
DT, time to BCR, and Gleason score to predict clinical progression
after BCR (Pound et al., 1999). Parameters that magniﬁed the risk
of systemic relapse included a PSA-DT ≤3months, time to BCR
≤3 years, and Gleason score ≥7 (Freedland et al., 2005).
IMAGING
Traditional imaging to evaluate BCR involves either a bone scan
or computed tomography scan (CT scan) or Magnetic Resonance
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Imaging (MRI) studies (Nguyen et al., 2007). These techniques
are suboptimal for the evaluation of the patient with BCR with
serum PSA levels below 10 ng/ml (Cher et al., 1998; Novo et al.,
2006). The role of endorectal MRI is limited in evaluation of
the patients with BCR because of the low signal intensity of T2
weighted images in radiated tissue (Sugimura et al., 1990; Nudell
et al., 2000). Magnetic Resonance Spectroscopy (MRS) measures
elevation in choline or decrease in citrate in prostate cancer tissue
(Coakley et al., 2004) with a reported sensitivity of 77% compared
to 68% with MRI only. Newer MRI techniques under investigation
include Dynamic Contrast Enhanced MRI, which measures early
gadolinium washout in prostate cancer (Rouviere et al., 2004) and
Diffusion MRI imaging that measure degree of cellular crowding
(Kim et al., 2009).
Radiolabeled imaging such as the ProstaScint scan or the tra-
ditional FDG PET scan has not lived up to the initial promise in
evaluating the extent of the recurrent prostate cancer (Thomas
et al., 2003). Recently, investigational PET tracers may have util-
ity in evaluating the extent of the recurrent disease in the BCR
state. For patients with BCR and PSA levels <2.5 ng/ml, 11C-
choline PET in one study was reported to have a sensitivity of
89% and a positive predictive value of 72% (Rinnab et al., 2009).
Similarly, 18F-choline PET sensitivity and speciﬁcity in detecting
bone metastases from prostate cancer was reported to be 79 and
97%, respectively (Beheshti et al., 2010). Currently, there is no
uniformly accepted imaging modality that can distinguish local
versus systemic recurrence.
BIOPSY
Prostate biopsy can be used to conﬁrm local relapse in cases of
palpable disease on the DRE after initial local therapy. The routine
use of such biopsies is not warranted (Koppie et al., 2001). Fur-
ther, the interpretation of the biopsy after RT is associated with
high false-positive results and requires experienced pathologists
(Molinie et al., 2008).
OPTIONS FOR SALVAGE THERAPY
Patients with systemic recurrence are not candidates for local-
ized salvage therapies, such as salvage RP, salvage RT, or salvage
cryotherapy. Systemic therapies such as ADT may be appropri-
ate for patients with systemic recurrences. The management of
patients with recurrences is nuanced and should include an assess-
ment of the risk-beneﬁt ratio of intervention and patient pref-
erences. Critical assessment using life expectancy tables (Cowen
et al., 2006) and clinical progression nomograms (Pound et al.,
1999; D’Amico et al., 2005; Freedland et al., 2005) may help decide
on the need for observation or intervention with salvage therapy.
Since every salvage local therapy or systemic therapy for patients
with BCR is associated with a signiﬁcant risk of complications,
these interventions must be judiciously used. A thorough evalua-
tion of patients prior to initiation of salvage local therapies to rule
out systemic disease and thus avoid the unwanted side effects of
salvage local therapies is an absolute must.
SALVAGE RT
If every patient with BCR after primary RP underwent salvage
RT, less than half of these patients would beneﬁt. Salvage RT after
primary RP has been associated with a 4-year progression-free
probability of 45% (Stephenson et al., 2004a). Patients with Glea-
son score 8–10, pre-RT PSA>2.0 ng/ml, positive surgical margins,
seminal vesicle involvement (SVI) and/or PSA-DT ≤10months
had a higher risk of recurrence after salvage RT. A salvage RT
nomogram that calculates the 6-year BCR-free probability may
help identify patients who may best beneﬁt from salvage RT
(Stephenson et al., 2007). Patients at high-risk for recurrence on
the salvage RT nomogram should be spared from the toxicity of
salvage RT, which includes bladder irritation, radiation cystitis,
radiationproctitis, impotence, and the long-term risk of secondary
malignancies.
For patients undergoing salvage RT, the extension of the radi-
ation ﬁeld from prostatic fossa-alone to include the full pelvis
including obturator nodes may further decrease recurrence rates
after salvage RT (Kim et al., 2004; Spiotto et al., 2007). High-
risk patients receiving both ADT and RT had a recurrence rate
of 52.7% if the whole pelvis was radiated compared to 18.2% for
patients with prostate fossa-alone radiation (Spiotto et al., 2007).
Additionally, the concomitant use of ADT to salvage RT may also
decrease recurrence rates (Bolla, 2005). The subset of patients with
SVI on the RP specimen had the greatest beneﬁt from the addition
of ADT to salvage RT (King et al., 2004).
SALVAGE RP
Salvage RP may be offered to patients with biopsy proven prostate-
only recurrence after primary RT. Salvage RP may be associated
with a signiﬁcant rate of post-operative incontinence (44–77%),
bladder neck contractures (22–41%), and rectal injury (2–10%;
Ward et al., 2005; Sanderson et al., 2006). In experienced hands,
salvage RP can be safely performed with minimal complications
(Eastham). The 5-year disease free survival has been reported to
be 61% (Amling et al., 1999) with a 17–36% PCSM (Cheng et al.,
1998; Bianco et al., 2005; Sanderson et al., 2006). Surgical mar-
gin status at the time of salvage RP is an important factor in
predicting biochemical recurrence-free survival (BRFS). Negative
margins correlated with 80% BRFS compared to 44% in patients
with positive margins (Garzotto and Wajsman, 1998). The use of
nerve-sparing approach helped in preservation of erectile func-
tion in some patients (Stephenson et al., 2004b). Newer reports
of robotic-assisted salvage prostatectomy are showing promising
results (Boris et al., 2009).
SALVAGE CRYOTHERAPY
This therapy has recently emerged as an alternative less inva-
sive procedure in the treatment of localized BCR with a 5-year
BRFS of 42% (Izawa et al., 2002). The oncologic efﬁcacy of
salvage cryotherapy was more pronounced in low-risk patients
(BRFS= 73%) than in intermediate (BRFS= 45%) or high-risk
patients (BRFS= 11%; Ismail et al., 2007). Salvage cryotherapy is
associated with a signiﬁcant complications, including up to 73%
of urinary incontinence and 72% of erectile dysfunction (Pisters
et al., 1997).
ANDROGEN DEPRIVATION THERAPY
Systemic options are centered around theuse of ADTasmonother-
apy (Cooperberg et al., 2003). ADT is associated with an ini-
tial dramatic shrinkage of tumors, long-term control of serum
PSA and signiﬁcant relief of symptoms for metastatic disease. A
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FIGURE 2 | Proposed algorithm for BCR management.
majority of patients with BCR are managed by ADT, including
60% of patients who underwent primary RP and 94% of patients
who received primary RT (Agarwal et al., 2008). However, the use
of ADT for non-metastatic BCR-only disease is controversial, as
it is neither benign nor associated with an advantage in overall
survival. The side effects from prolonged ADT is associated with
potentially signiﬁcant hot ﬂashes, increased bone turnover, osteo-
porosis, loss of muscle mass, and increased fracture risk, sexual
dysfunction, and loss of libido, memory loss, increased fat depo-
sition, altered lipid proﬁles, and a signiﬁcantly increased risk of
cardiovascular events and cardiovascular morbidity (Saigal et al.,
2007; Tsai et al., 2007). These side effects have prompted evalua-
tion of either delaying initiation of ADT until either metastases
or a pre-deﬁned serum PSA level could both offer the bene-
ﬁts of ADT and minimize the potential side effects. Evaluation
of early versus delayed ADT in 1352 men with BCR showed a
delay in clinical progression with early ADT only in men with
high-risk features (Gleason ≥8 or PSA-DT ≤10months; Moul
et al., 2004). Alternatively, the use of intermittent ADT in men
with BCR may offer both PSA control and minimize side effects,
with ADT initiated or reinitiated at pre-deﬁned PSA levels. In
order to prevent the potentially crippling skeletal complications
associated withADT (Saad et al., 2004), Zoledronic acid (Zometa),
and Denosumab (Xgeva) may be used in patients with metastatic
disease, while Denosumab (Prolia) may be used in patients with
non-metastatic BCR.
CONCLUSION
The management of patients with BCR after deﬁnitive local ther-
apy to the prostate is still not well deﬁned and complex. Most
men with BCR will DOCs than their disease. Currently, the major-
ity of these patients are treated with ADT, despite its signiﬁcant
detrimental side effects. Critical evaluation of these patients and
the risk-beneﬁt ratio of each intervention must be performed to
ascertain their optimal individualized management.
An algorithm describing our approach to patients with BCR is
detailed (Figure 2). Patients with radiographically localized BCR
and low-risk of failure of salvage therapies should be identiﬁed
using available nomograms and offered the choice of either obser-
vation or a potentially curable salvage local therapy. Patients at
high-risk for failure of salvage therapies should be offered either
immediate ADT or delayed ADT upon either a predeﬁned PSA
value or metastasis. Alternatively, these patients should be offered
a clinical trial.
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